Anaptysbio (ANAB) Amortizatization of Intangibles (2020 - 2026)
Anaptysbio posted quarterly Amortizatization of Intangibles of $480000.0 for Q1 2026, up 4.35% year-on-year from $460000.0 in Q1 2025, and up 1.05% on a QoQ basis from $475000.0 in Q4 2025.
Anaptysbio (ANAB) has 7 years of Amortizatization of Intangibles data on file, last reported at $480000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 4.35% year-over-year to $480000.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 4.15% YoY), and the FY2025 full-year result was $1.9 million, up 4.08% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $480000.0, up from $475000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $876000.0 in Q4 2022 and bottomed at -$161000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $452000.0 (2024), against an average of $442294.1.
- The widest annual swing landed in 2022, when Amortizatization of Intangibles slumped 227.78%; it then jumped 365.22% in 2023.
- A 5-year view of Amortizatization of Intangibles shows it stood at $876000.0 in 2022, then plunged by 49.89% to $439000.0 in 2023, then grew by 3.87% to $456000.0 in 2024, then grew by 4.17% to $475000.0 in 2025, then rose by 1.05% to $480000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $480000.0 (Q1 2026), $475000.0 (Q4 2025), and $470000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - | 480,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 480,000.00 |
| Mar 31, 2026 | 480,000.00 |
| Dec 31, 2025 | 475,000.00 |
| Dec 31, 2025 | 475,000.00 |
| Sep 30, 2025 | 470,000.00 |
| Sep 30, 2025 | 470,000.00 |
| Jun 30, 2025 | 459,000.00 |
| Jun 30, 2025 | 459,000.00 |
| Mar 31, 2025 | 460,000.00 |
| Mar 31, 2025 | 460,000.00 |
| Dec 31, 2024 | 456,000.00 |
| Dec 31, 2024 | 456,000.00 |
| Sep 30, 2024 | 452,000.00 |
| Sep 30, 2024 | 452,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Mar 31, 2024 | 442,000.00 |
| Mar 31, 2024 | 442,000.00 |
| Dec 31, 2023 | 439,000.00 |
| Dec 31, 2023 | 439,000.00 |
| Sep 30, 2023 | 434,000.00 |
| Sep 30, 2023 | 434,000.00 |
| Jun 30, 2023 | 424,000.00 |
| Jun 30, 2023 | 424,000.00 |
| Mar 31, 2023 | 427,000.00 |
| Mar 31, 2023 | 427,000.00 |
| Dec 31, 2022 | 876,000.00 |
| Dec 31, 2022 | 876,000.00 |
| Sep 30, 2022 | 784,000.00 |
| Sep 30, 2022 | 784,000.00 |
| Jun 30, 2022 | 161,000.00 |
| Jun 30, 2022 | 161,000.00 |
| Mar 31, 2022 | -161,000.00 |
| Mar 31, 2022 | -161,000.00 |
| Dec 31, 2021 | 220,000.00 |
| Dec 31, 2021 | 220,000.00 |
| Sep 30, 2021 | 500,000.00 |
| Sep 30, 2021 | 500,000.00 |
| Jun 30, 2021 | 625,000.00 |
| Jun 30, 2021 | 625,000.00 |
| Mar 31, 2021 | 126,000.00 |
| Mar 31, 2021 | 126,000.00 |
| Dec 31, 2020 | 479,000.00 |
| Dec 31, 2020 | 479,000.00 |
| Sep 30, 2020 | 197,000.00 |
| Sep 30, 2020 | 197,000.00 |